Literature DB >> 20727673

RAD001 shows activity against gastric cancer cells and overcomes 5-FU resistance by downregulating thymidylate synthase.

Kyung-Hun Lee1, Hyung-Seok Hur, Seock-Ah Im, Juhee Lee, Hwang-Phill Kim, Young-Kwang Yoon, Sae-Won Han, Sang-Hyun Song, Do-Youn Oh, Tae-You Kim, Yung-Jue Bang.   

Abstract

We evaluated RAD001, an inhibitor of the mammalian target of rapamycin (mTOR) in human gastric cancer cell lines and determined the molecular mechanisms. RAD001 has marked growth inhibitory activity against the SNU-1 and SNU-216 cells. It inhibited phosphorylation of mTOR and S6K, and induced G1 cell cycle arrest. Synergistic growth-inhibitory effects in combination with 5-fluorouracil (5-FU) was identified. Furthermore, RAD001 conferred sensitivity to 5-FU-resistant cell lines by downregulating thymidylate synthase (TS). In conclusion, RAD001 showed growth inhibitory activity against gastric cancer cells and acted synergistically with cytotoxic agents such as 5-FU by downregulating TS.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20727673     DOI: 10.1016/j.canlet.2010.07.020

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  17 in total

1.  Glutaminolysis and carcinogenesis of oral squamous cell carcinoma.

Authors:  Marcel Cetindis; Thorsten Biegner; Adelheid Munz; Peter Teriete; Siegmar Reinert; Martin Grimm
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-02-07       Impact factor: 2.503

Review 2.  Targeted therapies for gastric cancer: current status.

Authors:  Jaclyn Yoong; Michael Michael; Trevor Leong
Journal:  Drugs       Date:  2011-07-30       Impact factor: 9.546

3.  Molecular targeted therapies in advanced gastric cancer: does tumor histology matter?

Authors:  Hilda Wong; Thomas Yau
Journal:  Therap Adv Gastroenterol       Date:  2013-01       Impact factor: 4.409

4.  Phase II trial of capecitabine and everolimus (RAD001) combination in refractory gastric cancer patients.

Authors:  Su Jin Lee; Jongtae Lee; Jeeyun Lee; Se Hoon Park; Joon Oh Park; Young Suk Park; Ho Yeong Lim; Kyoung-Mee Kim; In-Gu Do; Sin-Ho Jung; Dong-Seok Yim; Won Ki Kang
Journal:  Invest New Drugs       Date:  2013-09-07       Impact factor: 3.850

5.  B7-H3 increases thymidylate synthase expression via the PI3k-Akt pathway.

Authors:  Bo Jiang; Fen Liu; ZhiHui Liu; Ting Zhang; Dong Hua
Journal:  Tumour Biol       Date:  2016-01-20

6.  circEXOC6B interacting with RRAGB, an mTORC1 activator, inhibits the progression of colorectal cancer by antagonizing the HIF1A-RRAGB-mTORC1 positive feedback loop.

Authors:  Xiaomin Li; Jianjun Wang; Weihao Lin; Qinzi Yuan; Yanxia Lu; Haowei Wang; Yujia Chen; Lixia Chen; Peiling Dai; Huaicheng Long; Xuenong Li
Journal:  Mol Cancer       Date:  2022-06-23       Impact factor: 41.444

7.  Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study.

Authors:  Atsushi Ohtsu; Jaffer A Ajani; Yu-Xian Bai; Yung-Jue Bang; Hyun-Cheol Chung; Hong-Ming Pan; Tarek Sahmoud; Lin Shen; Kun-Huei Yeh; Keisho Chin; Kei Muro; Yeul Hong Kim; David Ferry; Niall C Tebbutt; Salah-Eddin Al-Batran; Heind Smith; Chiara Costantini; Syed Rizvi; David Lebwohl; Eric Van Cutsem
Journal:  J Clin Oncol       Date:  2013-09-16       Impact factor: 44.544

8.  NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations.

Authors:  Eunju Park; Jinah Park; Sae-Won Han; Seock-Ah Im; Tae-You Kim; Do-Youn Oh; Yung-Jue Bang
Journal:  Int J Oncol       Date:  2011-12-08       Impact factor: 5.650

9.  Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies.

Authors:  Maarten J Deenen; Heinz-Josef Klümpen; Dick J Richel; Rolf W Sparidans; Mariette J Weterman; Jos H Beijnen; Jan H M Schellens; Johanna W Wilmink
Journal:  Invest New Drugs       Date:  2011-08-02       Impact factor: 3.850

10.  The novel mTOR inhibitor CCI-779 (temsirolimus) induces antiproliferative effects through inhibition of mTOR in Bel-7402 liver cancer cells.

Authors:  Shuyu Li; Yan Liang; Manlin Wu; Xiaojing Wang; Haixia Fu; Yuhao Chen; Zhigang Wang
Journal:  Cancer Cell Int       Date:  2013-03-28       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.